Cargando…

Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark

AIM: Resources devoted to health care are limited, therefore setting priorities is required. It differs between countries whether decision-making concerning health care technologies focus on broad economic perspectives or whether focus is narrow on single budgets (“silo mentality”). The cost perspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulsen, Peter Bo, Johnsen, Søren Paaske, Hansen, Morten Lock, Brandes, Axel, Husted, Steen, Harboe, Louise, Dybro, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644544/
https://www.ncbi.nlm.nih.gov/pubmed/29066923
http://dx.doi.org/10.2147/CEOR.S145813
_version_ 1783271744280199168
author Poulsen, Peter Bo
Johnsen, Søren Paaske
Hansen, Morten Lock
Brandes, Axel
Husted, Steen
Harboe, Louise
Dybro, Lars
author_facet Poulsen, Peter Bo
Johnsen, Søren Paaske
Hansen, Morten Lock
Brandes, Axel
Husted, Steen
Harboe, Louise
Dybro, Lars
author_sort Poulsen, Peter Bo
collection PubMed
description AIM: Resources devoted to health care are limited, therefore setting priorities is required. It differs between countries whether decision-making concerning health care technologies focus on broad economic perspectives or whether focus is narrow on single budgets (“silo mentality”). The cost perspective as one part of the full health economic analysis is important for decision-making. With the case of oral anticoagulants in patients with nonvalvular atrial fibrillation (NVAF), the aim is to discuss the implication of the use of different cost perspectives for decision-making and priority setting. METHODS: In a cost analysis, the annual average total costs of five oral anticoagulants (warfarin and non-vitamin K oral anticoagulants [NOACs; dabigatran, rivaroxaban, apixaban, and edoxaban]) used in daily clinical practice in Denmark for the prevention of stroke in NVAF patients are analyzed. This is done in pairwise comparisons between warfarin and each NOAC based on five potential cost perspectives, from a “drug cost only” perspective up to a “societal” perspective. RESULTS: All comparisons of warfarin and NOACs show that the cost perspective based on all relevant costs, ie, total costs perspective, is essential for the choice of therapy. Focusing on the reimbursement costs of the drugs only, warfarin is the least costly option. However, with the aim of therapy to prevent strokes and limit bleedings, including the economic impact of this, all NOACs, except rivaroxaban, result in slightly lower health care costs compared with warfarin. The same picture was found applying the societal perspective. CONCLUSION: Many broad cost-effectiveness analyses of NOACs exist. However, in countries with budget focus in decision-making this information does not apply. The present study’s case of oral anticoagulants has shown that decision-making should be based on health care or societal cost perspectives for optimal use of limited resources. Otherwise, the risk is that suboptimal decisions will be likely.
format Online
Article
Text
id pubmed-5644544
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56445442017-10-24 Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark Poulsen, Peter Bo Johnsen, Søren Paaske Hansen, Morten Lock Brandes, Axel Husted, Steen Harboe, Louise Dybro, Lars Clinicoecon Outcomes Res Original Research AIM: Resources devoted to health care are limited, therefore setting priorities is required. It differs between countries whether decision-making concerning health care technologies focus on broad economic perspectives or whether focus is narrow on single budgets (“silo mentality”). The cost perspective as one part of the full health economic analysis is important for decision-making. With the case of oral anticoagulants in patients with nonvalvular atrial fibrillation (NVAF), the aim is to discuss the implication of the use of different cost perspectives for decision-making and priority setting. METHODS: In a cost analysis, the annual average total costs of five oral anticoagulants (warfarin and non-vitamin K oral anticoagulants [NOACs; dabigatran, rivaroxaban, apixaban, and edoxaban]) used in daily clinical practice in Denmark for the prevention of stroke in NVAF patients are analyzed. This is done in pairwise comparisons between warfarin and each NOAC based on five potential cost perspectives, from a “drug cost only” perspective up to a “societal” perspective. RESULTS: All comparisons of warfarin and NOACs show that the cost perspective based on all relevant costs, ie, total costs perspective, is essential for the choice of therapy. Focusing on the reimbursement costs of the drugs only, warfarin is the least costly option. However, with the aim of therapy to prevent strokes and limit bleedings, including the economic impact of this, all NOACs, except rivaroxaban, result in slightly lower health care costs compared with warfarin. The same picture was found applying the societal perspective. CONCLUSION: Many broad cost-effectiveness analyses of NOACs exist. However, in countries with budget focus in decision-making this information does not apply. The present study’s case of oral anticoagulants has shown that decision-making should be based on health care or societal cost perspectives for optimal use of limited resources. Otherwise, the risk is that suboptimal decisions will be likely. Dove Medical Press 2017-10-13 /pmc/articles/PMC5644544/ /pubmed/29066923 http://dx.doi.org/10.2147/CEOR.S145813 Text en © 2017 Poulsen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Poulsen, Peter Bo
Johnsen, Søren Paaske
Hansen, Morten Lock
Brandes, Axel
Husted, Steen
Harboe, Louise
Dybro, Lars
Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title_full Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title_fullStr Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title_full_unstemmed Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title_short Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
title_sort setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in denmark
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644544/
https://www.ncbi.nlm.nih.gov/pubmed/29066923
http://dx.doi.org/10.2147/CEOR.S145813
work_keys_str_mv AT poulsenpeterbo settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT johnsensørenpaaske settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT hansenmortenlock settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT brandesaxel settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT hustedsteen settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT harboelouise settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark
AT dybrolars settingprioritiesinthehealthcaresectorthecaseoforalanticoagulantsinnonvalvularatrialfibrillationindenmark